Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trelegy

- PMLiVE

AZ links with Abbott on personalised asthma diagnostic

Diagnostic would aim to identify patients most likely to respond to tralokinumab

- PMLiVE

GSK shelves ViiV sale as it lays out growth strategy

Firm now bullish on the HIV joint pharma project’s prospects

- PMLiVE

Prescribing costs jump in England

New report finds that asthma and diabetes drugs the most costly to the NHS

- PMLiVE

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

UK to pay for GSK’s MenB vaccine after year’s delay

British firm says the deal offers ‘fair value’ to the NHS

- PMLiVE

FDA panel backs GSK’s asthma drug Breo for adults only

Already approved to treat COPD in the US

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

PMCPA ‘appalled’ by Chiesi’s Code of Practice breach

Ethics watchdog says firm mislead it in a "completely unacceptable" manner

- PMLiVE

AZ gets injunction to protect Pulmicort Respules

Actavis blocked from selling generic five days after AZ’s asthma launch

- PMLiVE

GSK first to file IL-5 antagonist for asthma

Mepolizumab submitted as a treatment for severe eosinophilic asthma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links